GA-D can reverse the resistance to gemcitabine (GEM) in triple-negative breast cancer (TNBC), activating the p53/MDM2 pathway, promoting the ubiquitination and proteasomal degradation of HIF-1α, downregulating HIF-1α-dependent glycolytic genes such as GLUT1, HK2, and PKM2, and significantly reducing the growth of GEM-resistant TNBC cells [109]. Here, HIF1A is linked to triple-negative breast carcinoma.